122 related articles for article (PubMed ID: 36648658)
1. [Not Available].
Zidek W
MMW Fortschr Med; 2023 Jan; 165(1):28. PubMed ID: 36648658
[No Abstract] [Full Text] [Related]
2. [Benefits of spironolactone as the optimal treatment for drug resistant hypertension. Pathway-2 trial review].
Prado JC; Ruilope LM; Segura J
Hipertens Riesgo Vasc; 2016; 33(4):150-154. PubMed ID: 27363610
[TBL] [Abstract][Full Text] [Related]
3. Spironolactone in the treatment of hypertension: a neglected molecule.
Veselý J
Vnitr Lek; 2018; 64(7-8):815-820. PubMed ID: 30441987
[TBL] [Abstract][Full Text] [Related]
4. Should All Patients with Resistant Hypertension Receive Spironolactone?
Rosa J; Zelinka T; Petrák O; Štrauch B; Holaj R; Widimský J
Curr Hypertens Rep; 2016 Nov; 18(11):81. PubMed ID: 27787836
[TBL] [Abstract][Full Text] [Related]
5. A meta-analysis of add-on use of spironolactone in patients with resistant hypertension.
Zhao D; Liu H; Dong P; Zhao J
Int J Cardiol; 2017 Apr; 233():113-117. PubMed ID: 28089457
[TBL] [Abstract][Full Text] [Related]
6. [PATHWAY-2 Study: spironolactone vs placebo, bisoprolol and doxazosin to determine optimal treatment of resistant hypertension. Spironolactone high effective in lowering blood pressure in drug resistant hypertension].
Widimský J
Vnitr Lek; 2015 Dec; 61(12):1067-71. PubMed ID: 26806502
[TBL] [Abstract][Full Text] [Related]
7. Addition of spironolactone in patients with resistant hypertension: A meta-analysis of randomized controlled trials.
Liu L; Xu B; Ju Y
Clin Exp Hypertens; 2017; 39(3):257-263. PubMed ID: 28448185
[TBL] [Abstract][Full Text] [Related]
8. [PRELIMINARY NOTE ON THE TREATMENT OF ARTERIAL HYPERTENSION BY SPIRONOLACTONE ADMINISTRATION].
CHARMOT G; ANDRE LJ; LAFFITE A; BOUCHEAU P; LAGARDE B
Mars Med; 1964; 101():558-63. PubMed ID: 14177121
[No Abstract] [Full Text] [Related]
9. [Double-blind therapeutic trial of spironolactone in arterial hypertension].
Chávez-Domínguez R; Sánchez-Torres G; Serrano P
Arch Inst Cardiol Mex; 1975; 45(4):487-94. PubMed ID: 1101838
[TBL] [Abstract][Full Text] [Related]
10. [Detection of the optimal dose of spironolactone for the treatment of benign essential hypertension].
Rhomberg F
Schweiz Med Wochenschr; 1977 Sep; 107(35):1228-32. PubMed ID: 335498
[TBL] [Abstract][Full Text] [Related]
11. Spironolactone in essential hypertension: evidence against its effect through mineralocorticoid antagonism.
Hoffbrand BI; Edmonds CJ; Smith T
Br Med J; 1976 Mar; 1(6011):682-4. PubMed ID: 766908
[TBL] [Abstract][Full Text] [Related]
12. Spironolactone Reduces Aortic Stiffness in Patients With Resistant Hypertension Independent of Blood Pressure Change.
Aryal SR; Siddiqui M; Sharifov OF; Coffin MD; Zhang B; Gaddam KK; Gupta H; Denney TS; Dell'Italia LJ; Oparil S; Calhoun DA; Lloyd SG
J Am Heart Assoc; 2021 Sep; 10(17):e019434. PubMed ID: 34459249
[TBL] [Abstract][Full Text] [Related]
13. Failure of aspirin to antagonize the antihypertensive effect of spironolactone in low-renin hypertension.
Hollifield JW
South Med J; 1976 Aug; 69(8):1034-6. PubMed ID: 785608
[TBL] [Abstract][Full Text] [Related]
14. The role of spironolactone in the treatment of patients with refractory hypertension.
Ouzan J; Pérault C; Lincoff AM; Carré E; Mertes M
Am J Hypertens; 2002 Apr; 15(4 Pt 1):333-9. PubMed ID: 11991219
[TBL] [Abstract][Full Text] [Related]
15. The effect of spironolactone (Aldactone) and methyldopa in low and normal renin hypertension.
Solheim SB; Sundsfjord JA; Giezendanner L
Acta Med Scand; 1975 Jun; 197(6):451-6. PubMed ID: 1098396
[TBL] [Abstract][Full Text] [Related]
16. Spironolactone Versus Clonidine as a Fourth-Drug Therapy for Resistant Hypertension: The ReHOT Randomized Study (Resistant Hypertension Optimal Treatment).
Krieger EM; Drager LF; Giorgi DMA; Pereira AC; Barreto-Filho JAS; Nogueira AR; Mill JG; Lotufo PA; Amodeo C; Batista MC; Bodanese LC; Carvalho ACC; Castro I; Chaves H; Costa EAS; Feitosa GS; Franco RJS; Fuchs FD; Guimarães AC; Jardim PC; Machado CA; Magalhães ME; Mion D; Nascimento RM; Nobre F; Nóbrega AC; Ribeiro ALP; Rodrigues-Sobrinho CR; Sanjuliani AF; Teixeira MDCB; Krieger JE;
Hypertension; 2018 Apr; 71(4):681-690. PubMed ID: 29463627
[TBL] [Abstract][Full Text] [Related]
17. A systematic review and meta-analysis of effects of spironolactone on blood pressure, glucose, lipids, renal function, fibrosis and inflammation in patients with hypertension and diabetes.
Lin M; Heizati M; Wang L; Nurula M; Yang Z; Wang Z; Abudoyreyimu R; Wu Z; Li N
Blood Press; 2021 Jun; 30(3):145-153. PubMed ID: 33682538
[TBL] [Abstract][Full Text] [Related]
18. Spironolactone Use and Improved Outcomes in Patients With Heart Failure With Preserved Ejection Fraction With Resistant Hypertension.
Tsujimoto T; Kajio H
J Am Heart Assoc; 2020 Dec; 9(23):e018827. PubMed ID: 33222584
[TBL] [Abstract][Full Text] [Related]
19. Resistant Hypertension in Chronic Kidney Disease (CKD): Prevalence, Treatment Particularities, and Research Agenda.
Georgianos PI; Agarwal R
Curr Hypertens Rep; 2020 Sep; 22(10):84. PubMed ID: 32880742
[TBL] [Abstract][Full Text] [Related]
20. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial.
Agarwal R; Rossignol P; Romero A; Garza D; Mayo MR; Warren S; Ma J; White WB; Williams B
Lancet; 2019 Oct; 394(10208):1540-1550. PubMed ID: 31533906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
